spacer
home > ict > spring 2020 > from zero to sixty: why yesterday’s eclinical trial horizon is today’s reality
PUBLICATIONS
International Clinical Trials

From Zero to Sixty: Why Yesterday’s eClinical Trial Horizon Is Today’s Reality






On 11 March 2020, WHO officially declared the rapidly spreading COVID-19 outbreak as a pandemic. The first in years, this pandemic caused the world to change its social behaviours in just a few weeks. Now, living in a post-COVID-19 society, several industries have been forced to stress test the capabilities of their remote work environment. The clinical trials industry is no exception. As a result, ideas that were once touted as ‘next generation’ during keynotes just a few years ago are now being put to the test in live trial environments. However, it’s not just the ‘shiny and new’ technologies on the front lines of post- COVID-19 trials. Instead, it’s a unique blend of eClinical technologies, new and old. This mix, combined with strong processes and quick thinking, has helped lay the foundation for our industry’s rapid pivot towards remote work.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the company

The best technology succeeds in the background. Signant Health provides solutions that simplify every step of the patient journey to make it easier for people to participate in, and for sites and study teams to run, clinical trials. Signant unites eCOA, eConsent, patient engagement, interactive response technology, clinical supplies, and endpoint quality into the industry’s most comprehensive patient-centric suite – an evolution built on more than 20 years of proven clinical research technology. Our intense focus on the patient experience, deep therapeutic area expertise, and global operational scale enable hundreds of sponsors and CROs (including all top 20 pharmaceutical companies) to extend the reach of drug development, expand patient opportunities, and improve data quality – helping them bring lifechanging therapies to our families and communities around the world.

hello@signanthealth.com

www.signanthealth.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

PhoreMost Enters Multi-Project Drug Target Discovery Collaboration With Roche

Cambridge, UK, 06 September 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Roche, one of the world's leading biotechnology companies. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.
More info >>

White Papers

8 Ways To Reduce Tablet Manufacturing Costs

Natoli Engineering Company, Inc.

It’s no surprise that in today’s economy, companies are facing budget cuts across the board. In an effort to address these challenges, this list of 8 Ways to Reduce Tablet Manufacturing Costs was compiled.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement